ProfileGDS5678 / 1434205_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 93% 94% 93% 94% 93% 93% 92% 92% 93% 92% 92% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9922894
GSM967853U87-EV human glioblastoma xenograft - Control 27.935393
GSM967854U87-EV human glioblastoma xenograft - Control 37.8472293
GSM967855U87-EV human glioblastoma xenograft - Control 48.2443294
GSM967856U87-EV human glioblastoma xenograft - Control 57.9523893
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.7525894
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.6339793
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.8758193
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.6614692
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7605192
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.7519993
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.7870492
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.7479392
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.7192192